Pre-implantation Genetic Testing (PGT)

Pre-implantation Genetic Testing for Aneuploidies (PGT-A) and Pre-implantation Genetic Testing for Monogenic Defects/Structural Rearrangements (PGT-M/-SR) are the latest genetic tests performed on embryos to identify chromosomal abnormalities or single gene disorders.

1. Pre-implantation Genetic Testing for Aneuploidies (PGT-A) uses the rapid technology Chromosomal Microarray Analysis (CMA) or the new Next-generation Sequencing (NGS) to evaluate the total number of chromosomes in several cells of the embryo and determines any gain or loss of each chromosome or a small chromosome segment down to 10Mb in size.
2. Pre-implantation Genetic Testing for Monogenic Defects/Structural Rearrangements (PGT-M/-SR) is used to test for monogenic disorders or structural rearrangements to make it possible to transfer an embryo free of the genetic disease under consideration and avoid selective termination of pregnancy.

Who is eligible for Pre-implantation Genetic Testing (PGT) and benefit from it

• Advanced maternal age (age 35 or over)
• Recurrent miscarriages
• Repeated implantation failures
• Severe male factor infertility

Benefits of Pre-implantation Genetic Testing (PGT)

-  PGT-A identifies euploid embryos for intrauterine
transfer and its potential advantages include:

• Improve the implantation rate in those with repeated implantation failures
• Reduce the risk of early pregnancy loss in couples with recurrent pregnancy loss
• Reduce the risk of birth defects
• Improve the chance of live birth of a healthy baby
• Reduce the risk of multiple pregnancies by single embryo transfer

-  PGT-M/-SR identifies the embryo which does not carry the targeted genetic mutations or structural rearrangements for intrauterine transfer to avoid the inheritance of the patient’s disease gene.